Summary
Thirty percent of adult patients with Hodgkin's disease fail primary treatment or relapse after treatment. Whereas overall mortality for Hodgkin's disease is about 20%, half the patients who relapse will die.
Among patients with refractory or relapsing disease, about a third can be rescued by conventional salvage treatment. Unfortunately, except for patients with late relapse, remission after conventional salvage treatment is generally not of long duration.
However, durable complete remissions can now be achieved in nearly a third of patients with refractory or relapsing disease by means of very aggressive (myeloablative) chemotherapy with consecutive autologous bone marrow transplantation (aBMT).
The rate of durable complete remissions seems to be even higher if previous exposure to chemotherapeutic agents is not in excess of two different treatment protocols (optimal timing of aBMT) and if responsiveness to cytotoxic drugs is preserved (low degree of drug resistance).
Bone marrow transplantation should be restricted to patients whose resulting long-term prognosis justifies such radical treatment. Reflecting ongoing clinical therapy-studies, in particular in Germany, the role of bone marrow transplantation in a general concept of salvage treatment should be pointed out. Patients should be considered candidates if they fail alternating primary chemotherapy or develop an early relapse after this treatment, but still show responsiveness to chemotherapeutic agents.
Similar content being viewed by others
Abbreviations
- aBMT:
-
autologous bone marrow transplantation
- pS:
-
pathological staging
- C[M]OPP/ABVD:
-
Cyclophosphamide [Mustargen], Vincristine (Oncovin), Procarbazine, Prednisone/Doxorubicin (Adriamycin), Bleomycin, Vinblastine, Dacarbazine
- CEVD:
-
Lomustine (CCNU), Etoposide, Vindesine, Dexamethasone
- Dexa-BEAM:
-
Dexamethasone, Carmustine (BCNU), Etoposide, Cytarabin (Ara-C), Melphalan
- COPP/ABV/IMEP:
-
Cyclophosphamide, Vincristine (Oncovin), Procarbazine, Prednisone/Doxorubicin, Bleomycin, Vindesine/Ifosfamide, Methotrexate, Etoposide, Prednisone
- CEP:
-
Lomustine (CCNU), Etoposide, Prednimustine
- MIME:
-
Mitoguazone, Ifosfamide, Methotrexate, Etoposide
- CVB:
-
Cyclophosphamide, Etoposide (Vepeside), Carmustine (BCNU)
- CR:
-
complete remission
- n.r.:
-
not reported
References
Anderson KC, Ritz J, Takvorian T, Coral F, Daley H, Gorgone BC, Freedman AS, Canellos GP, Schlossman SF, Nadler LM (1987) Hematologic engraftment and immune reconstitution post-transplantation with anti-B1 purged autologous bone marrow. Blood 69:597–604
Appelbaum FR, Sullivan KM, Thomas ED, Buckner CD, Clift RA, Deeg HJ, Neimann PJ, Sanders JE, Stewart P, Storb R (1985) Allogenic marrow transplantation in the treatment of MOPP-resistant Hodgkin's disease. J clin Oncol 3:1490–1494
Appelbaum FR, Sullivan KM, Buckner CD, Clift RA, Deeg HJ, Fefer A, Hill R, Mortimer J, Neimann PE, Sanders JE, Singer J, Stewart P, Storb R, Thomas ED (1987) Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irridation, and marrow transplantation. J clin Oncol 5:1340–1347
Armitage JO (1989) Bone marrow transplantation in the treatment of patients with lymphoma. Blood 73:1749–1758
Bonadonna G, Valagussa P, Santoro A (1986) Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. Ann intern Med 104:739–746
Bregni M, Lappi DA, Siena S, Formosa A, Villa S, Soria M, Bonadonna G, Gianni AM (1988) Activity of monoclonal antibody-saporin-6 conjugate against B-lymphoma cells. J Natl Cancer Inst 80 (7): 511–517
Buzaid AC, Lippman SM, Miller TP (1987) Salvage therapy of advanced Hodgkin's disease. Am J Med 83:523–532
Carella M, Congiu A, Mazza P, Gaozza E, Ricci P, Visani G, Meloni G, Cimino G, Mangoni L, Coser P, Cetto GL, Cimino R, Alessandrino EP, Brusaliamo E, Santini G, Tura S, Mandelli F, Rizzoli V, Bernasconi C, Marmont AM (1988a) High-dose chemotherapy with autologous BMT “rescue” in advanced resistant Hodgkin's disease. An Italian retrospective study group. J clin Oncol 6:1411–1416
Carella M, Marmont AM (1988b) Salvage treatment for advanced resistant Hodkin's lymphoma: the role of bone marrow transplantation. Haematologica 73:93–99
Cervantes F, Reverter JC, Montserrat E, Rozman C (1986) Treatment of advanced resistant Hodgkin's disease with lomustine etoposide and prednimustine. Cancer Treatm Rep 70:665–667
Diehl V, Dühmke E, Georgii, Fischer, Hübner, Schwarze (1989) BMFT-Studie zum Morbus Hodgkin des Erwachsenen. Studienprotokolle HD 4, HD 5 und HD 6. Kurzfassung für Chemo- und Strahlentherapeuten. Studienprotokoll der Deutschen Hodgkinstudiengruppe (3. korrigierte Fassung 8/89) Köln, S 13
Fefer A (1986) Current status of syngenic marrow transplantation and its relevance to autografting. Clin Hemat 15:49–65
Fisher RI, De Vita VT, Hubbard SP, Simon R, Young RC (1979) Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse. Ann intern Med 90:761–763
Fox K, Lippman SM, Cassady JR, Hensinkveld RS, Miller TP (1987) Radiation therapy salvage of Hodgkin's disease following chemotherapy failure. J clin Oncol 5:38–45
Gribben JG, Linch DC, Singer CR, Mc Millan AK, Jarrett M, Goldstone AH (1989) Successful treatment of refractory Hodgkin's disease by high-dose combination chemotherapy and autologous bone marrow transplantation. Blood 73:340–344
Hagemeister FB, Fuller LM, Sullivan JA, Johnston D, North L, Butler JJ, Velasquez WS, Shullenberger C (1982) Treatment of patients with stages I and II nonmediastinal Hodgkin's disease. Cancer 50:2307–2313
Hagemeister FB, Tannir N, Mc Laughlin P, Salvador P, Riggs S, Velasquez WS, Cabanillas F (1987) MIME chemotherapy (Methyl-GAG, Ifosfamide, Methotrexate, Etoposide) as treatment for recurrent Hodgkin's disease. J clin Oncol 5:556–561
Harker WG, Kushlan P, Rosenberg S (1984) Combination chemotherapy for advanced Hodgkin's disease after failure of MOPP: ABVD and B-CAVe. Ann intern Med 101:440–446
Hoppe RT, Coleman CN, Cox RS, Rosenberg SA, Kaplan HS (1982) The management of stage I–II Hodgkin's disease with irridation alone or combined modality therapy: the Stanford experience. Blood 59:455–465
Jagannath S, Armitage JO, Dicke KA, Tucker SL, Velasquez WE, Smith K, Vaughan WP, Kessinger A, Horwitz LH, Hagemeister FB, Mc Laughlin P, Cabanillas F, Spitzer G (1989) Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease. J clin Oncol 7:179–185
Kessinger A, Armitage JO, Landmark JD, Smith DM, Weisenburger DD (1988) Autologous peripheral hematopoietic stem cell transplantation restores hematopoietic function following marrow ablative therapy. Blood 71:723–727
Loeffler M, Pfreundschuh M, Hasenclever D, Hiller E, Ger-hartz H, Wilmans W, Rohloff R, Rühl U, Kühn G, Fuchs R, Kirchner H, Teichmann J, Schoppe W, Petsch S, Wilhelmy W, Worst P, Pflüger KH, Hecht T, Bartels H, Gassmann W, Krüger G, Schmitz G, Oertel W, Diehl V (1988) Prognostic risk factors in advanced Hodgkin's lymphoma. Blut 56:273–281
Mascret B, Maraninchi D, Gastaut JA, Tubiang N, Sebahoun G, Horschowski N, Ainty D, Camerlo J, Lejeune C, Norvakovitch G, Carcassone Y (1986) Treatment of malignant lymphoma with high-dose of chemo- or chemoradiotherapy and bone marrow transplantation. Eur J Cancer clin Oncol 22:461–471
Pfreundschuh M, Schoppe WD, Fuchs R, Pflüger KH, Loeffler M, Diehl V (1987) Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). A Multicenter trial of the German Hodgkin Study Group. Cancer Treatm Rep 71:1203–1207
Pfreundschuh M, Diehl V (1989a) Therapie rezidivierender Hodgkin-Lymphome. Teil I. Strahlentherapie und konventionelle Chemotherapie. Dtsch med Wochenschr 114:880–884
Pfreundschuh M, Diehl V (1989b) Therapie rezidivierender Hodgkin-Lymphome. Teil II. Stellenwert der Knochen-marktransplantation. Dtsch med Wochenschr 114:916–921
Pfreundschuh M (1989c) Randomisierte Placebo-kontrollierte Studie zur Dosiseskalation in der Kombinationstherapie Dexamethason/BCNU/Etoposid/Ara-C/Melphalan (Dexa-BEAM) unter GM-CSF Applikation bei Patienten mit refraktären und rezidivierenden Hodgkin-Lymphomen. Protokollentwurf 6/89 für die Deutschen Hodgkinstudiengruppe, Köln, S 1–14
Pfreundschuh M, Schaadt M, Diehl V (1989d) Conventional Salvage Therapy for Hodgkin's Lymphoma. In: Recent Results in Cancer Research: New Aspects in the Diagnosis and Treatment of Hodgkin's Disease. (1. Ed) Springer, Berlin Heidelberg New York, pp 225–232
Philip T, Armitage JO, Spitzer G, Chauvin F, Jagannath S, Cahn JH, Colombat P, Goldstone A, Gorin NC, Flesh M, Laporte JP, Maraninchi D, Pico J, Bosly A, Anderson C, Schots R, Biron P, Cabanillas F, Dicke K (1987) Highdose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med 316:1493–1498
Phillips GL, Reece DE (1986a) Clinical studies of autologous bone marrow transplantation in Hodgkin's disease. Clin Hemat 15:151–166
Phillips GL, Herzig RH, Lazarus HM, Fay JW, Herzig GP (1986b) High-dose chemotherapy, fractionated total body irridation and allogenic BMT for malignant lymphomas. J clin Oncol 4:480–488
Phillips GL, Reece DE, Barnett MJ, Connors JM, Fay JW, Herzig GP, Herzig RH, Klingmann HG, Shepherd JD, Wolff SN (1989a) Allogenic marrow transplantation for refractory Hodgkin's disease. J clin Oncol 7:1039–1045
Phillips GL, Wolff SN, Herzig RH, Lazarus HM, Fay JW, Lin HS, Shina DC, Glasgow GP, Griffith RC, Lamb CW, Herzig GP (1989b) Treatment of progressive Hodgkin's disease with intensive chemoradiotherapy and autologous bone marrow transplantation. Blood 73:2086–2092
Santoro A, Bonfante V, Bonadonna G (1982) Salvage chemotherapy with ABVD in MOPP-resistant Hodgkin's disease. Ann intern Med 96:139–143
Santoro A, Bonadonna G, Bonfante V, Valagussa P (1982) Alternating drug combinations in the treatment of advanced Hodgkin's disease. N Engl J Med 306:770–775
Santoro A, Viviani S, Valagussa P, Bonfante V, Bonadonna G (1986) CCNU, etoposide, and prednimustine (CEP) in refractory Hodgkin's disease. Semin Oncol 13, Suppl 1:23–26
Schmitz N, Gassmann W, Kayser W, Löffler H (1987) Autologe Knochenmarktransplantation bei Morbus Hodgkin. Dtsch med Wochenschr 112:314–320
Skipper HE, Schabel FM, Wilcox WS (1964) Experimental evaluation of potential anticancer agents. XII. On the criteria and kinetics associated with “curability” of experimental leukemia. Cancer Chemother Rep 55:1–111
Zagars G, Rubin P (1985) Laparotomy-staged IA versus IIA Hodgkin's disease. Cancer 56:864–873
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Thomas, M., Gattermann, N. & Schneider, W. Refractory and relapsing Hodgkin's disease: Role of high-dose chemotherapy with bone marrow transplantation. Klin Wochenschr 68, 539–544 (1990). https://doi.org/10.1007/BF01667145
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01667145